You are here

Press Releases

Sep 08, 2015

DURLAZA is the First and Only Once-Daily, Prescription Low Dose, Extended-release Aspirin Designed for Secondary Prevention in Patients at Risk of Recurrent Life-Threatening Thrombotic Events

May 22, 2015

Aims: Low-dose acetylsalicylic acid (ASA; aspirin) for secondary prevention reduces cardiovascular disease mortality risk. ASA acetylates cyclooxygenase in the portal circulation and is rapidly (half-life, 20 min) hydrolyzed.

Oct 08, 2014

Branford, CT - New Haven Pharmaceuticals, Inc. (the "Company" or "NHP"), a privately-held specialty pharmaceuticals company, has strengthened its management team with the appointment of Dr. Jeffrey Patrick as Chief Scientific Officer.


Subscribe to News